GSK: story ‘unfair'

Share this article:
GlaxoSmithKline's director of CME took exception with a Wall Street Journal report on GSK-funded med ed.

The December 2006 article asserts that GSK paid for a series of lectures by doctors who favor universal screening and treatment of pregnant women for genital herpes (MM&M, January 2007), two contentious issues.

“Your article implies that the industry uses [CME] as a means to promote product; this unfairly taints the value that quality CME brings to healthcare professionals and to the patients,” wrote Bryan King, PharmD, director, GSK Center for Medical Education, in a letter to the editor.
GSK's Valtrex is not approved to prevent neonatal herpes in pregnant women.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.